Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Revenue (2020 - 2026)

Rani Therapeutics Holdings' Revenue history spans 5 years, with the latest figure at $1.7 million for Q1 2026.

  • On a quarterly basis, Revenue rose 893.02% to $1.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 164.08% increase, with the full-year FY2025 number at $1.6 million, up 58.85% from a year prior.
  • Revenue came in at $1.7 million for Q1 2026, up from $1.5 million in the prior quarter.
  • The five-year high for Revenue was $1.7 million in Q1 2026, with the low at $172000.0 in Q1 2025.
  • Historically, Revenue has averaged $1.1 million across 3 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Revenue: soared 42.12% in 2025 and later surged 893.02% in 2026.
  • Year by year, Revenue stood at $1.0 million in 2024, then surged by 42.12% to $1.5 million in 2025, then rose by 16.91% to $1.7 million in 2026.
  • Business Quant data shows Revenue for RANI at $1.7 million in Q1 2026, $1.5 million in Q4 2025, and $172000.0 in Q1 2025.